Please provide your email address to receive an email when new articles are posted on . Tonmya significantly reduced daily pain vs. placebo in a phase 3 trial in fibromyalgia. Fast track designation ...
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated ...
Treatment with DD01 treatment reduced hepatic steatosis by more than 50% in 4 weeks, according to phase 1 data. The Food and Drug Administration (FDA) has granted Fast Track designation to DD01 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback